381 related articles for article (PubMed ID: 26954690)
1. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.
Kawaguchi H; Shimada H; Kodaka F; Suzuki M; Shinotoh H; Hirano S; Kershaw J; Inoue Y; Nakamura M; Sasai T; Kobayashi M; Suhara T; Ito H
PLoS One; 2016; 11(3):e0151191. PubMed ID: 26954690
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
3. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
[TBL] [Abstract][Full Text] [Related]
4. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.
Martín-Bastida A; Lao-Kaim NP; Roussakis AA; Searle GE; Xing Y; Gunn RN; Schwarz ST; Barker RA; Auer DP; Piccini P
Brain; 2019 Jul; 142(7):2023-2036. PubMed ID: 31056699
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
[TBL] [Abstract][Full Text] [Related]
6. Normative data of dopaminergic neurotransmission functions in substantia nigra measured with MRI and PET: Neuromelanin, dopamine synthesis, dopamine transporters, and dopamine D
Ito H; Kawaguchi H; Kodaka F; Takuwa H; Ikoma Y; Shimada H; Kimura Y; Seki C; Kubo H; Ishii S; Takano H; Suhara T
Neuroimage; 2017 Sep; 158():12-17. PubMed ID: 28655632
[TBL] [Abstract][Full Text] [Related]
7. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.
Saari L; Kivinen K; Gardberg M; Joutsa J; Noponen T; Kaasinen V
Neurology; 2017 Apr; 88(15):1461-1467. PubMed ID: 28283599
[TBL] [Abstract][Full Text] [Related]
9. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder.
Pyatigorskaya N; Gaurav R; Arnaldi D; Leu-Semenescu S; Yahia-Cherif L; Valabregue R; Vidailhet M; Arnulf I; Lehéricy S
Sleep; 2017 Nov; 40(11):. PubMed ID: 28958075
[TBL] [Abstract][Full Text] [Related]
11. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
[TBL] [Abstract][Full Text] [Related]
12. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
13. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
[TBL] [Abstract][Full Text] [Related]
14. Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT.
Takahashi H; Kashiwagi N; Arisawa A; Matsuo C; Kato H; Adachi H; Kajiyama Y; Mochizuki H; Tomiyama N
Br J Radiol; 2022 Feb; 95(1130):20210837. PubMed ID: 34808066
[TBL] [Abstract][Full Text] [Related]
15. [
Coakeley S; Cho SS; Koshimori Y; Rusjan P; Ghadery C; Kim J; Lang AE; Houle S; Strafella AP
Brain Struct Funct; 2018 Mar; 223(2):589-595. PubMed ID: 28884232
[TBL] [Abstract][Full Text] [Related]
16. The utility of the combined use of
Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal DAT changes measured with [
Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
[TBL] [Abstract][Full Text] [Related]
18. Dopamine transporter imaging with [
Jakobson Mo S; Axelsson J; Jonasson L; Larsson A; Ögren MJ; Ögren M; Varrone A; Eriksson L; Bäckström D; Af Bjerkén S; Linder J; Riklund K
EJNMMI Res; 2018 Nov; 8(1):100. PubMed ID: 30443684
[TBL] [Abstract][Full Text] [Related]
19. Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease.
Furukawa K; Shima A; Kambe D; Nishida A; Wada I; Sakamaki H; Yoshimura K; Terada Y; Sakato Y; Mitsuhashi M; Sawamura M; Nakanishi E; Taruno Y; Yamakado H; Fushimi Y; Okada T; Nakamoto Y; Takahashi R; Sawamoto N
Ann Neurol; 2022 Jul; 92(1):110-121. PubMed ID: 35428994
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
